Catalyst Biosciences to Present at 32nd Annual Piper Sandler Virtual Healthcare Conference
November 24 2020 - 04:01PM
Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced it will
participate in the Piper Sandler 32nd Annual Virtual Healthcare
Conference taking place December 1-3, 2020. The pre-recorded
presentation is available for registered attendees via the Piper
Sandler conference site until December 3. It will also be available
on the Events and Presentations section on the Company’s
website for approximately 90 days.
Catalyst Biosciences will be participating in
1x1 meetings. Investors may request meetings with the management
via Piper Sandler.
About Catalyst
BiosciencesCatalyst is a research and clinical development
biopharmaceutical company focused on addressing unmet medical needs
in rare hematologic and complement-mediated disorders. Our protease
engineering platform generated two late-stage clinical programs in
hemophilia; a research program on engineering of subcutaneous (SQ)
complement inhibitors; a discovery stage Factor IX gene therapy
construct – CB2679d-GT – for Hemophilia B, and a partnered
preclinical development program with Biogen for dry age-related
macular degeneration (AMD). The product candidates generated by our
protease engineering platform have improved functionality and
potency that allow for: SQ administration of recombinant
coagulation factors and complement inhibitors; low-dose, high
activity gene therapy constructs; and less frequently dosed
intravitreal therapeutics. Our most advanced product candidate is
marzeptacog alfa (activated) (MarzAA), a next-generation SQ FVIIa
entering a Phase 3 registration study in late 2020. Our next
late-stage product candidate is dalcinonacog alfa (DalcA), a
next-generation SQ FIX, which has demonstrated efficacy and safety
in a Phase 2b clinical trial in individuals with Hemophilia B. We
have a discovery stage Factor IX gene therapy construct - CB
2679d-GT - for Hemophilia B, that has demonstrated superiority
compared with the Padua variant in preclinical models. Finally, we
have a global license and collaboration agreement with Biogen for
the development and commercialization of anti-complement Factor 3
(C3) pegylated CB 2782.
Forward-Looking Statements
This press release contains forward-looking
statements that involve substantial risks and uncertainties.
Forward-looking statements include statements about candidates
generated by Catalyst’s protease engineering platform having
improved functionality and potency, Catalyst’s plans to enroll the
first patient in a Phase 3 open-label trial of MarzAA and the
Company’s collaboration with Biogen for the development and
commercialization of pegylated CB 2782 Actual results or events
could differ materially from the plans, intentions, expectations
and projections disclosed in the forward-looking statements.
Various important factors could cause actual results or events to
differ materially, including, but not limited to, the risk that
trials and studies may be delayed as a result of COVID-19 and other
factors, that trials may not have satisfactory outcomes, that
additional human trials will not replicate the results from earlier
trials, that potential adverse effects may arise from the testing
or use of MarzAA, including the generation of neutralizing
antibodies, the risk that costs required to develop or manufacture
the Company’s products will be higher than anticipated, including
as a result of delays in development and manufacturing resulting
from COVID-19 and other factors, the risk that Biogen will
terminate Catalyst’s agreement, competition and other risks
described in the “Risk Factors” section of the Company’s quarterly
report filed with the Securities and Exchange
Commission on November 5, 2020, and in other filings with
the Securities and Exchange Commission. The Company does not
assume any obligation to update any forward-looking statements,
except as required by law.
Contact:
Ana KaporCatalyst Biosciences, Inc.investors@catbio.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Mar 2023 to Mar 2024